Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDTekla Life Sciences Investors Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Tekla Life Sciences Investors Earnings Date And Information
Tekla Life Sciences Investors last posted its earnings results on N/A. The company reported $N/A earnings per share for the quarter, missing analysts' consensus estimates of $N/A by $0. The company had revenue of 1.91 M for the quarter and had revenue of 86.69 M for the year. Tekla Life Sciences Investors has generated $0 earnings per share over the last year ($0 diluted earnings per share) and currently has a price-to-earnings ratio of 4.38. Tekla Life Sciences Investors has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, December 9th, 2024 based on prior year's report dates.
Tekla Life Sciences Investors Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/30/2024 | Q4 2024 | N/A | $1.22 | N/A | $1.91 M | $1.91 M |
| 03/29/2024 | Q2 2024 | N/A | $1.84 | N/A | $2.07 M | $2.07 M |
| 09/28/2023 | Q4 2023 | N/A | -$0.43 | N/A | N/A | $29.56 M |
| 03/29/2023 | Q2 2023 | N/A | $1.22 | N/A | N/A | $-6,040,429 |
| 09/29/2022 | Q4 2022 | N/A | -$1.10 | N/A | N/A | $21.69 M |
| 03/30/2022 | Q2 2022 | N/A | -$3.03 | N/A | N/A | $10.17 M |
| 09/29/2021 | Q4 2021 | N/A | $1.34 | N/A | N/A | $15.98 M |
| 03/30/2021 | Q2 2021 | N/A | $1.30 | N/A | N/A | $29.03 M |
| 09/29/2020 | Q4 2020 | N/A | $3.91 | N/A | N/A | $16.50 M |
| 03/30/2020 | Q2 2020 | N/A | $1.29 | N/A | N/A | $22.57 M |
| 09/29/2019 | Q4 2019 | N/A | -$1.33 | N/A | N/A | $1.31 M |
| 03/31/2019 | Q2 2019 | N/A | -$1.72 | N/A | N/A | $1.13 M |
| 09/29/2018 | Q4 2018 | N/A | $2.12 | N/A | N/A | $988,762 |
| 03/31/2018 | Q2 2018 | N/A | -$0.90 | N/A | N/A | $997,061 |
| 09/29/2017 | Q4 2017 | N/A | $1.94 | N/A | N/A | $891 |
| 03/30/2017 | Q2 2017 | N/A | $1.26 | N/A | N/A | $791 |
| 09/29/2016 | Q4 2016 | N/A | $2.76 | N/A | N/A | $722 |
| 03/30/2016 | Q2 2016 | N/A | -$3.44 | N/A | N/A | $716 |
| 09/29/2015 | Q4 2015 | N/A | -$2.56 | N/A | N/A | $835 |
| 03/30/2015 | Q2 2015 | N/A | $4.72 | N/A | N/A | $488 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Tekla Life Sciences Investors Earnings: FAQ's
Tekla Life Sciences Investors has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, December 9th, 2024 based offlast year's report dates.
The conference call for Tekla Life Sciences Investors's latest earnings report can be listened to online.
The conference call transcript for Tekla Life Sciences Investors's latest earnings report can be read online.
Tekla Life Sciences Investors (:HQL) has a recorded annual revenue of $86.69 M.
Tekla Life Sciences Investors (:HQL) has a recorded net income of $85.30 M.Tekla Life Sciences Investors has generated $0 earnings per share over the last four quarters.
Tekla Life Sciences Investors (:HQL) has a price-to-earnings ratio of 4.38 and price/earnings-to-growth ratio is 0.04.